Clinical trial
Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
NCT00061048 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00061048 |
|---|---|
| Title | Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma |
| Official title | Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute T-Cell Leukemia-Lymphoma |
| Intervention type | Biological |
| Interventions | Alemtuzumab |
| Enrollment | 29 |
| Start date | May 1, 2003 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2012 |
| First posted | May 21, 2003 |
| Last update posted | Oct 31, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: